Conference Program Home
My Program
All Times EDT
Legend:
CC = Walter E. Washington Convention Center M = Marriott Marquis Washington, DC
* = applied session ! = JSM meeting theme
Activity Details
|
|
|
|
233 * !
|
Tue, 8/9/2022,
8:30 AM -
10:20 AM
|
CC-144B
|
|
Statistical Considerations for Adjusting Overall Survival in Randomized Trials with Treatment Switching — Topic Contributed Papers
|
|
Biopharmaceutical Section, Biometrics Section, International Statistical Institute
|
|
Organizer(s): Songzi Li, BeiGene, Ltd.
|
|
Chair(s): Hongqian Wu, BeiGene
|
|
8:35 AM
|
A Simulation Study of Treatment Switching Considering Delay Treatment Effect
Songzi Li, BeiGene, Ltd.; Jiang Li, Ph.D
|
|
8:55 AM
|
The Least Bad Option: A Simulation Approach to Minimizing Bias When Accounting for Treatment Switching in RCTs
Daniel Leibovitz, Bristol Myers Squibb; Alessandro Previtali, Bristol Myers Squibb; Revathi Ananthakrishnan, Bristol Myers Squibb; James Lymp, Bristol Myers Squibb
|
|
9:15 AM
|
Estimation of Treatment Effects and Model Diagnostics with Two-Way, Time-Varying Treatment Switching
Qingxia Chen, Vanderbilt University Medical Center; Fan Zhang, Pfizer Inc., Groton, CT. This work was done at University of Connecticut.; Ming-Hui Chen, University of Connecticut; Xiuyu Julie Cong, Everest Medicines, Shanghai, China. This work was done at Boehringer Ingelheim Pharma.
|
|
9:35 AM
|
Bayesian Model for Overall Survival Analysis Allowing Treatment Switching in Oncology Trials
Zhou Feng, FDA; Erik Bloomquist, Ph.D.
|
|
9:55 AM
|
Discussant: Chi Song, FDA
|
|
10:15 AM
|
Floor Discussion
|
Video Available to all JSM Registered Attendees. Please login to view.
|
